News You Can Use…

Josh Stewart, PharmD Candidate 2016

Pete Koval, PharmD

Cone Health Family Medicine

October 2015

Drug Approval Extension

• Spiriva (tiotropium) is now FDA-approved in asthma with Respimat • Was previously only indicated for COPD • Asthma dose: 2 inh once daily of 1.25mcg

(1.25mcg x 2 inhalations) = total 2.5mcg• COPD dose: 2.5mcg X 2 inh = total 5mcg

09/16/15 boehringer-ingelheim.com

New Drug Approval

• Veltassa (patiromer) gained FDA approval for hyperkalemia• Not indicated for acute treatment• Used for patients with chronic

hyperkalemia on RAAS inhibitors

10/22/2015 FDA.gov

New Drug Approval

• The FDA has approved the use of Aristada (aripiprazole lauroxil) extended release injection to treat schizophrenia

• It is the 2nd once-monthly aripiprazole injection approved by the FDA (Abilify Maintena)

10/06/2015 FDA.gov

New Drug Approval

• Dyanavel XR (amphetamine) has been approved by the FDA for the treatment of ADHD in children 6 years and older

• It is an oral suspension that contains both extended-release and immediate-release properties

10/20/2015 prenewswire.com

Generic Drug Availability

• Paliperidone (Invega) is now available as a generic formulation

• It is indicated for treatment of schizophrenia in patients 12 and older

9/29/2015 PharmacyTimes.com

P&T Committee

• Ivabradine (Corlanor®) is now on Cone Health’s formulary

• Indicated for reduction of hospitalizations in people with worsening heart failure who meet the following criteria:• Stable symptomatic CHF with LVEF <35%

• In sinus rhythm with resting heart rate > 70 bpm

• On maximally tolerated beta blockers or have a contraindication to beta blocker use

10/21/15 Cone Health P & T

P&T Committee

• Rapivab (peramivir) will NOT be added to the Cone Health formulary

• Injectable antiviral for influenza

• Concerns: high cost, IV formulation, not approved for pediatric use

10/21/2015 Cone Health P & T

Trial Review

• Jardiance (empagliflozin) showed CV and mortality benefit in diabetic patients against placebo in a recent study• Patients randomized to empagliflozin

10mg, 25mg, or placebo for >3 years• Patients on empagliflozin showed a lower

rate of cardiovascular events and death from any cause

9/17/2015 N Engl J Med